Literature DB >> 8694665

Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators.

.   

Abstract

OBJECTIVE: To define contemporary patterns of risk and management among patients with congestive heart failure (CHF).
METHODS: Cross-sectional records audit of 4606 hospitalized patients with CHF in 1992 and 1993.
RESULTS: Overall medication use was diuretics, 82%; angiotensin-converting enzyme inhibitors, 53%; nitrates, 49%; digoxin, 46%; potassium, 40%; acetylsalicylic acid, 36%; calcium antagonists, 20%; warfarin, 17%; beta-blockers, 15%; and magnesium, 10%. Angiotensin-converting enzyme inhibitors were used less frequently in women and patients 70 years or older (P < .01). Total in-hospital mortality was 19%. The most common single cause of death was CHF progression, but noncardiac causes accounted for 30% of all deaths. Logistic regression analysis revealed age 70 years or older and the use of magnesium and nitrates to be associated with increased relative risk of in-hospital mortality; angiotensin-converting enzyme inhibitors, acetylsalicylic acid, calcium antagonists, beta-blockers, and warfarin were associated with decreased risk.
CONCLUSIONS: Hospitalized patients with CHF have high all-cause mortality risk and less than optimal use of proven efficacious therapy, particularly among women and the elderly. Increased use of proven CHF therapy would likely decrease the risk of cardiac events, but the competing non-cardiac risks in this patient population are high and may not be affected by improved use of efficacious cardiac therapies.

Entities:  

Mesh:

Year:  1996        PMID: 8694665

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

Review 1.  Antiarrhythmic therapies for the prevention of sudden cardiac death.

Authors:  F A McAlister; K K Teo
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.

Authors:  F Andersson; C Cline; T Rydén-Bergsten; L Erhardt
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 3.  Underutilisation of ACE inhibitors in patients with congestive heart failure.

Authors:  T J Bungard; F A McAlister; J A Johnson; R T Tsuyuki
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project.

Authors:  Saif S Rathore; JoAnne Micale Foody; Yongfei Wang; Jeph Herrin; Frederick A Masoudi; Edward P Havranek; Diana L Ordin; Harlan M Krumholz
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

5.  Revascularization in patients with heart failure.

Authors:  Ross T Tsuyuki; Fiona M Shrive; P Diane Galbraith; Merril L Knudtson; Michelle M Graham
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

6.  Cardiac-specific overexpression of dominant-negative CREB leads to increased mortality and mitochondrial dysfunction in female mice.

Authors:  Peter A Watson; Nicholas Birdsey; Gordon S Huggins; Eric Svensson; Daniel Heppe; Leslie Knaub
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

7.  Gender and drug treatment as determinants of mortality in a cohort of heart failure patients.

Authors:  A Ruigómez; S Johansson; M A Wallander; L A García Rodríguez
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

8.  Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study.

Authors:  Ali Ahmed; Richard M Allman; Gregg C Fonarow; Thomas E Love; Faiez Zannad; Louis J Dell'italia; Michel White; Mihai Gheorghiade
Journal:  J Card Fail       Date:  2008-04       Impact factor: 5.712

9.  Does heart failure therapy differ according to patient sex?

Authors:  Josep Lupón; Agustín Urrutia; Beatriz González; Crisanto Díez; Salvador Altimir; Carlos Albaladejo; Teresa Pascual; Celestino Rey-Joly; Vicente Valle
Journal:  Clin Cardiol       Date:  2007-06       Impact factor: 2.882

10.  A cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328].

Authors:  Sumit R Majumdar; Finlay A McAlister; Ross T Tsuyuki
Journal:  BMC Cardiovasc Disord       Date:  2005-06-27       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.